VI Technologies' Unattributed VC - III Round

VI Technologies raised a round of funding on February 20, 2004.

Vitex is developing products designed to improve the safety of the world's blood supply. The Company's proprietary INACTINE technology, currently in a Phase III clinical trial, is designed to inactiva…

Articles about VI Technologies' Unattributed VC - III Round: